

Amendments to the Claims

1. (currently amended) A ~~composition~~ condensation aerosol for delivery of benzotropine ~~consisting of a condensation aerosol~~ a drug selected from the group consisting of benzotropine, pergolide, amantadine, deprenyl and ropinerole,

a) ~~wherein the condensation aerosol is formed by volatilizing~~ heating a thin layer of benzotropine containing the drug, on a solid support, ~~having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of benzotropine~~ the drug and condensing the ~~heated vapor of benzotropine~~ to form a condensation aerosol ~~partieles,~~

~~— b) wherein said condensation aerosol particles are~~ characterized by less than 5% benzotropine 10% drug degradation products by weight, and

~~e) the condensation aerosol has an MMAD of less than 3~~ 5 microns.

2. (currently amended) The ~~composition~~ condensation aerosol according to Claim 1, wherein the condensation aerosol ~~particles are~~ is formed at a rate of ~~at least~~ greater than 10^9 particles per second.

3. (currently amended) The ~~composition~~ condensation aerosol according to Claim 2, wherein the condensation aerosol ~~particles are~~ is formed at a rate of ~~at least~~ greater than 10^{10} particles per second.

4. (currently amended) The ~~composition~~ condensation aerosol according to Claim ~~1~~ 38, wherein ~~said the~~ condensation aerosol ~~particles are~~ is characterized by less than 2.5% benzotropine drug degradation products by weight.

5-19. (cancelled)

20. (currently amended) A method of producing benzotropine ~~a drug selected from the group consisting of benzotropine, pergolide, amantadine, deprenyl and ropinerole~~ in an aerosol form comprising:

a. heating a thin layer ~~of benzotropine~~ containing the drug, on a solid support, ~~having the~~

~~surface texture of a metal foil, to a temperature sufficient to volatilize the benzotropine to form a heated vapor of the benzotropine drug, and~~

b. ~~during said heating, passing air providing an air flow through the heated vapor to produce a condensation aerosol particles of the benzotropine comprising characterized by less than 5% benzotropine 10% drug degradation products by weight, and an aerosol having an MMAD of less than 3~~
5 microns.

21. (currently amended) The method according to Claim 20, wherein the condensation aerosol ~~particles are~~ is formed at a rate of greater than 10^9 particles per second.

22. (currently amended) The method according to Claim 21, wherein the condensation aerosol ~~particles are~~ is formed at a rate of greater than 10^{10} particles per second.

23-34. (cancelled)

35. (new) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

36. (new) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

37. (new) The condensation aerosol according to Claim 36, wherein the condensation aerosol is characterized by an MMAD of 0.2 and 3 microns.

38. (new) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

39. (new) The condensation aerosol according to Claim 1, wherein the thin layer contains at least 80% drug by weight.

40. (new) The condensation aerosol according to Claim 39, wherein the thin layer contains at

least 95% drug by weight.

41. (new) The condensation aerosol according to Claim 1, wherein the condensation aerosol comprises at least 80% drug by weight.

42. (new) The condensation aerosol according to Claim 41, wherein the condensation aerosol comprises at least 95% drug by weight.

43. (new) The method according to Claim 1, wherein the thin layer has a thickness between 0.004 and 3 microns.

44. (new) The condensation aerosol according to Claim 1, wherein the solid support has the surface texture of a metal foil.

45. (new) The condensation aerosol according to Claim 1, wherein the solid support is a metal foil.

46. (new) The condensation aerosol according to Claim 1, wherein the drug is benzotropine.

47. (new) The condensation aerosol according to Claim 1, wherein the drug is pergolide.

48. (new) The condensation aerosol according to Claim 1, wherein the drug is amantadine.

49. (new) The condensation aerosol according to Claim 1, wherein the drug is deprenyl.

50. (new) The condensation aerosol according to Claim 1, wherein the drug is ropinerole.

51. (new) The method according to Claim 20, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

52. (new) The method according to Claim 20, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

53. (new) The method according to Claim 52, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.

54. (new) The method according to Claim 20, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

55. (new) The method according to Claim 54, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

56. (new) The method according to Claim 20, wherein the thin layer contains at least 80% drug by weight.

57. (new) The method according to Claim 56, wherein the thin layer contains at least 95% drug by weight.

58. (new) The method according to Claim 20, wherein the condensation aerosol comprises at least 80% drug by weight.

59. (new) The method according to Claim 58, wherein the condensation aerosol comprises at least 95% drug by weight.

60. (new) The method according to Claim 20, wherein the thin layer has a thickness between 0.004 and 3 microns.

61. (new) The method according to Claim 20, wherein the solid support has the surface texture of a metal foil.

62. (new) The method according to Claim 20, wherein the solid support is a metal foil.

63. (new) The method according to Claim 20, wherein the drug is benzotropine.

64. (new) The method according to Claim 20, wherein the drug is pergolide.

Serial No. 10/816,567

Amendment dated May 31, 2005

Response to Office Action dated November 30, 2004

- 65. (new) The method according to Claim 20, wherein the drug is amantadine.
- 66. (new) The method according to Claim 20, wherein the drug is deprenyl.
- 67. (new) The method according to Claim 20, wherein the drug is ropinerole.